Bismuth Subcitrate Potassium / Metronidazole / Tetracycline Dosage
Medically reviewed by Drugs.com. Last updated on Sep 6, 2023.
Applies to the following strengths: 140 mg-125 mg-125 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Helicobacter pylori Infection
Bismuth subcitrate potassium 420 mg-metronidazole 375 mg-tetracycline 375 mg orally 4 times a day (after meals and at bedtime)
- Duration of therapy: 10 days
- Omeprazole 20 mg should be given orally 2 times a day during treatment (after morning and evening meals).
- Helicobacter pylori eradication has been shown to reduce duodenal ulcer recurrence risk.
Use: Eradication of H pylori infection in patients with active or a history (e.g., within 5 years) of duodenal ulcer infection and/or disease
Renal Dose Adjustments
Mild to moderate renal dysfunction: Data not available
Severe renal dysfunction: Contraindicated
Liver Dose Adjustments
Mild to moderate liver dysfunction (Child-Pugh A and B): Use with caution; monitoring is recommended.
Severe liver dysfunction (Child-Pugh C): Not recommended.
- Hypersensitivity to any/all of the active components (including other nitroimidazole derivatives) or the ingredients
- Patients taking methoxyflurane concurrently
- Patients who consumed alcoholic beverages at least 3 days during/after treatment
- Severe renal dysfunction
- Use in pregnancy
- Use of disulfiram within the last 2 weeks
US BOXED WARNINGS:
POTENTIAL FOR CARCINOGENICITY:
- Metronidazole has been shown to be carcinogenic in mice and rats.
- It is unknown whether metronidazole is associated with carcinogenicity in humans.
Safety and efficacy have not been established in pediatric patients.
Consult WARNINGS section for additional precautions.
Data not available
- This drug should be given with a full glass of water (e.g., 8 ounces), especially the bedtime dose.
- If a dose is missed, patients should continue the normal dosing schedule; patients should not take double doses.
- Limitation of use: This drug should be used only to treat infections that are proven/strongly suspected to be caused by susceptible bacteria.
- DERMATOLOGIC: Erythema/photosensitivity, signs/symptoms of cutaneous reactions
- HEMATOLOGIC: Initial and post-treatment total and differential leukocyte counts, especially in patients with evidence/history of blood dyscrasias
- OCULAR: Ophthalmologic evaluation in patients who develop visual disturbances
- Tell patients that it is important to complete the full regimen.
- Instruct patients to seek medical attention if signs/symptoms of hypersensitivity, abnormal neurological effects, photosensitivity, or other cutaneous reactions occur.
- Patients should be told to avoid unprotected exposure to sunlight/UV light during treatment.
- Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.
More about bismuth subcitrate potassium / metronidazole / tetracycline
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (256)
- Imprints, shape & color data
- Side effects
- During pregnancy
- Drug class: H. pylori eradication agents
- En español
- Bismuth subcitrate potassium, metronidazole, and tetracycline drug information
- Bismuth subcitrate, metronidazole, and tetracycline (Advanced Reading)
- Bismuth Subcitrate, Metronidazole, and Tetracycline
Related treatment guides
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.